Maria Teresa Petrucci

17PUBLICATIONS
92CO-AUTHORS
Gene and molecular therapyMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 27, 2026
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

|Nov 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Sonia Morè, Massimo Offidani, Laura Corvatta

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|Jun 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595.

Nicola Sgherza, Olga Battisti, Paola Curci

|Apr 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.

Nicola Sgherza, Olga Battisti, Paola Curci

|Apr 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

Pageof 3

Frequent Collaborators

7 joint publications

Massimo Offidani

4 joint publications

Pellegrino Musto

4 joint publications

Francesca Fazio

3 joint publications

Francesca Gay